Publicaciones en colaboración con investigadores/as de Sahlgrenska University Hospital (11)

2024

  1. Penumbral Rescue by normobaric O = O administration in patients with ischemic stroke and target mismatch proFile (PROOF): Study protocol of a phase IIb trial

    International Journal of Stroke, Vol. 19, Núm. 1, pp. 120-126

2023

  1. Itga8-Cre-mediated deletion of YAP and TAZ impairs bladder contractility with minimal inflammation and chondrogenic differentiation

    American Journal of Physiology - Cell Physiology, Vol. 325, Núm. 6, pp. C1485-C1501

2022

  1. Multi-Ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke

    Brain, Vol. 145, Núm. 7, pp. 2394-2406

  2. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  3. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. Rp11-362k2.2:Rp11-767i20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma. a gwas meta-analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 14

  2. Single nucleotide variations in ZBTB46 are associated with post-thrombolytic parenchymal haematoma

    Brain, Vol. 144, Núm. 8, pp. 2416-2426

2013

  1. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

    PLoS Genetics, Vol. 9, Núm. 3

2012

  1. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

    Cancer Epidemiology Biomarkers and Prevention, Vol. 21, Núm. 4, pp. 645-657

2011

  1. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

    Breast Cancer Research, Vol. 13, Núm. 6

  2. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

    Journal of the National Cancer Institute, Vol. 103, Núm. 2, pp. 105-116